Nuuron, a Berlin, Germany-based neurotech startup, raised €3.5M in Seed funding.
The round was led by High-Tech Gründerfonds (HTGF) and included investors such as IBB Ventures, caesar., the Business Angel Club Berlin, other business angels and family offices.
The company intends to use the funds for animal studies in collaboration with the German Center for Neurodegenerative Diseases (DZNE) and a clinical trial with Alzheimer’s patients at Charité and to advance product development. Additionally, market entry preparations start in Europe and the U.S.
Founded by Fabian Queisner and Dr. Markus Müschenich, Nuuron is developing a fully digital Alzheimer’s therapy based on a proprietary neuromodulation technology. Its algorithms produce frequency, digital-photonic stimuli that activate the Memory System of Alzheimer’s patients, aiming to improve memory formation and memory recall. This digital disease-modifying therapy uses the retina as interface into the brain and employs advanced VR and AR technologies for stimulation delivery.
FinSMEs
31/10/2024